Richard Paul Baum
Overview
Explore the profile of Richard Paul Baum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruland O, Larsen R, Baum R, Juzeniene A
Front Med (Lausanne)
. 2023 Mar;
10:1165747.
PMID: 36960341
No abstract available.
2.
von Eyben F, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, et al.
Oncotarget
. 2019 May;
10(25):2451-2461.
PMID: 31069008
Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617,...
3.
von Eyben F, Baumann G, Baum R
Clin Transl Imaging
. 2018 Apr;
6(2):145-148.
PMID: 29670866
No abstract available.
4.
Rai B, Baum R, Patel A, Hughes R, Alonzi R, Lane T, et al.
Urology
. 2016 Jan;
95:11-5.
PMID: 26790588
The role of positron emission tomography (PET) with (68)Gallium (Ga)-labeled prostate-specific membrane antigen (PSMA) imaging for prostate cancer is gaining prominence. Current imaging strategies, despite having progressed significantly, have limitations,...
5.
Kaemmerer D, Athelogou M, Lupp A, Lenhardt I, Schulz S, Luisa P, et al.
Int J Clin Exp Pathol
. 2014 Sep;
7(8):4971-80.
PMID: 25197368
Background: Manual evaluation of somatostatin receptor (SSTR) immunohistochemistry (IHC) is a time-consuming and cost-intensive procedure. Aim of the study was to compare manual evaluation of SSTR subtype IHC to an...
6.
Peter L, Sanger J, Hommann M, Baum R, Kaemmerer D
Clin Nucl Med
. 2014 Feb;
39(8):713-6.
PMID: 24561680
Ga somatostatin receptor PET/CT, currently the most sensitive imaging modality for well-differentiated neuroendocrine tumors, is based on the molecular imaging of somatostatin receptors (SSTRs) that are expressed in different tumor...
7.
Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum R, et al.
Int J Clin Exp Pathol
. 2012 May;
5(3):187-94.
PMID: 22558472
Unlabelled: Neuroendocrine tumors (NET) are known for an overexpression of somatostatin receptors (SSTR). In light of very few and partially contradictory publications, the present study aims to achieve a definite...
8.
Salavati A, Prasad V, Schneider C, Herbst R, Baum R
Ann Nucl Med
. 2012 Feb;
26(4):365-9.
PMID: 22361935
Few studies have been published on the safety and feasibility of synchronous use of peptide receptor radionuclide therapy (PRRNT), as source of internal radiation therapy, in combination with chemotherapy. In...
9.
Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
Kaemmerer D, Khatib-Chahidi K, Baum R, Horsch D, Presselt N, Sanger J, et al.
Cancer Imaging
. 2011 Nov;
11:179-83.
PMID: 22123527
Well-differentiated neuroendocrine tumors (NETs) of the lung occur as typical and atypical carcinoids. Little is known about the biology of these tumors in respect of their ability to metastasize or...
10.
Calcagni M, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al.
Clin Nucl Med
. 2011 Sep;
36(10):841-7.
PMID: 21892031
Purpose: (1) To investigate the diagnostic value of some O-(2-[F]fluoroethyl)-L-tyrosine (F-18 FET) indices derived from the dynamic acquisition to differentiate low-grade gliomas from high-grade; (2) to analyze the course of...